$ONCO
Onconetix, Inc. Stock $onco

$onco Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023018635 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.766M	$2.040M	$9.352M
YoY Change	9.31%	166.35%	346.95%
% of Gross Profit
Research & Development	$1.082M	$1.206M	$4.130M
YoY Change	137.81%	175.68%	211.67%
% of Gross Profit
Depreciation & Amortization	$1.698K	$1.840K	$6.752K
YoY Change	30.62%	60.0%	38.08%
% of Gross Profit
Operating Expenses	$2.848M	$3.246M	$13.48M
YoY Change	37.55%	169.74%	294.5%
Operating Profit	-$2.848M		-$13.48M
YoY Change	37.55%		294.5%
Interest Expense	$1.620K	$28.04K	$61.41K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.615K		$61.41K
YoY Change
Pretax Income	-$2.847M	-$3.218M	-$13.42M
YoY Change	37.48%	167.41%	292.7%
Income Tax			$3159B
% Of Pretax Income
Net Earnings	-$2.847M	-$3.218M	-$13.42M
YoY Change	37.48%	167.41%	292.7%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.18		-$1.10
Diluted Earnings Per Share	-$0.18	-$0.20	-$1.10
COMMON SHARES
Basic Shares Outstanding	15.91M shares	15.47M shares	12.27M shares
Diluted Shares Outstanding	15.91M shares		12.27M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.26M	$25.75M	$25.75M
YoY Change	8.85%	1235.39%	1235.39%
Cash & Equivalents	$21.26M	$25.75M
Short-Term Investments
Other Short-Term Assets	$2.146M	$469.2K	$469.2K
YoY Change	552.74%	-52.71%	-52.71%
Inventory
Prepaid Expenses	$780.2K	$469.2K
Receivables
Other Receivables
Total Short-Term Assets	$22.47M	$26.26M	$26.26M
YoY Change	17.64%	754.41%	754.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.21K	$14.09K	$14.09K
YoY Change	-7.73%	22.49%	22.52%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$15.50K	$38.62K	$38.62K
YoY Change	-92.86%
Total Long-Term Assets	$29.71K	$52.71K	$52.71K
YoY Change	-87.22%	358.23%	358.35%
TOTAL ASSETS
Total Short-Term Assets	$22.47M	$26.26M	$26.26M
Total Long-Term Assets	$29.71K	$52.71K	$52.71K
Total Assets	$22.50M	$26.31M	$26.31M
YoY Change	16.38%	752.93%	752.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.503M	$1.499M	$1.499M
YoY Change	65.64%	157.34%	157.34%
Accrued Expenses	$1.293M	$2.409M	$2.409M
YoY Change	-31.71%	128.24%	128.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.809M	$3.922M	$3.922M
YoY Change	0.27%	139.45%	139.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.809M	$3.922M	$3.922M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.809M	$3.922M	$3.922M
YoY Change	0.27%	139.45%	139.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.22M	-$19.38M
YoY Change		225.29%
Common Stock	$164.00	$157.00
YoY Change		390.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$600.3K	$566.8K
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.69M	$22.39M	$22.39M
YoY Change
Total Liabilities & Shareholders Equity	$22.50M	$26.31M	$26.31M
YoY Change	16.38%	752.93%	752.93%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.847M	-$3.218M	-$13.42M
YoY Change	37.48%	167.41%	292.7%
Depreciation, Depletion And Amortization	$1.698K	$1.840K	$6.752K
YoY Change	30.62%	60.0%	38.08%
Cash From Operating Activities	-$4.446M	-$2.801M	-$8.699M
YoY Change	401.76%	315.36%	325.53%
INVESTING ACTIVITIES
Capital Expenditures	$1.819K	$0.00	$9.339K
YoY Change	-134.98%	-100.0%	-586.41%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.819K	$0.00	-$9.339K
YoY Change	-65.02%	-100.0%	386.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$566.8K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$48.95K	-582.8K	$32.53M
YoY Change	-100.28%	324.78%	-9834.7%
NET CHANGE
Cash From Operating Activities	-$4.446M	-2.801M	-$8.699M
Cash From Investing Activities	-$1.819K	0.000	-$9.339K
Cash From Financing Activities	-$48.95K	-582.8K	$32.53M
Net Change In Cash	-$4.497M	-3.384M	$23.82M
YoY Change	-126.96%	315.97%	-1100.87%
FREE CASH FLOW
Cash From Operating Activities	-$4.446M	-$2.801M	-$8.699M
Capital Expenditures	$1.819K	$0.00	$9.339K
Free Cash Flow	-$4.448M	-$2.801M	-$8.708M
YoY Change	404.93%	316.54%	326.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41294
CY2022	dei	Entity Registrant Name EntityRegistrantName	Blue Water Vaccines Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-2262816
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 E. Fifth Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1900
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Cincinnati
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	45202
CY2022	dei	City Area Code CityAreaCode	(513)
CY2022	dei	Local Phone Number LocalPhoneNumber	620-4101
CY2022	dei	Security12b Title Security12bTitle	Common stock, $0.00001 par value
CY2022	dei	Trading Symbol TradingSymbol	BWV
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	9800000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15911868	shares
CY2022	dei	Auditor Firm AuditorFirmId	199
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2022	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25752659	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1928474	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	469232	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	234551	usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	757646	usd
CY2022Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	35850	usd
CY2021Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	152524	usd
CY2021	bwv	Private Placement Warrants PrivatePlacementWarrants		shares
CY2022Q4	us-gaap	Assets Current AssetsCurrent	26257741	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3073195	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	38617	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14089	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11502	usd
CY2022Q4	us-gaap	Assets Assets	26310447	usd
CY2021Q4	us-gaap	Assets Assets	3084697	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1499296	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	582605	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2409128	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1055515	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	14021	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3922445	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1638120	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3922445	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1638120	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	bwv	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	bwv	Preferred Stock Shares Designated PreferredStockSharesDesignated	1150000	shares
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1146138	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1146138	shares
CY2021Q4	bwv	Preferred Stock Value1 PreferredStockValue1	11	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15724957	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3200000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15265228	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3200000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	157	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	32	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42331155	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7403204	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	459729	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	566810	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19376500	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5956670	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22388002	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1446577	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26310447	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3084697	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9351552	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2092304	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4129688	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1325030	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	13481240	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3417334	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13481240	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3417334	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-61410	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	61410	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13419830	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3417334	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	96359	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	627391	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13516189	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4044725	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.1
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.26
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12271449	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3200000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4733770	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	130141	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3417334	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1446577	usd
CY2022	bwv	Issuance Of Common Stock In Initial Public Offering Net IssuanceOfCommonStockInInitialPublicOfferingNet	2900000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17138840	usd
CY2022	bwv	Issuance Of Common Stock And Warrants In April Private Placement Net IssuanceOfCommonStockAndWarrantsInAprilPrivatePlacementNet	1100000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6858328	usd
CY2022	bwv	Issuance Of Common Stock And Warrants In Private Placement Net IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet	2200000	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	8689316	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1655	usd
CY2022	bwv	Exercise Of Prefunded Warrants1 ExerciseOfPrefundedWarrants1	1436	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	263924	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1974566	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	566810	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13419830	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22388002	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13419830	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3417334	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1974566	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	130141	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	263924	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-61410	usd
CY2022	us-gaap	Depreciation Depreciation	6752	usd
CY2021	us-gaap	Depreciation Depreciation	4890	usd
CY2021	bwv	Write Off Of Receivable From Related Party WriteOffOfReceivableFromRelatedParty	22242	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1199	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	234681	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8302	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	23326	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	114961	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	38617	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-184934	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1093913	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	336715	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1739849	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	809279	usd
CY2021	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	9642	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8698860	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2044235	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9339	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1924	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9339	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1924	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	334188	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	18400000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	-926972	usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	16468123	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	845048	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	566810	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1655	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1436	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32532384	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-334188	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	23824185	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2380347	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1928474	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4308821	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25752659	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1928474	usd
CY2021	bwv	Initial Public Offering Costs Included In Accounts Payable InitialPublicOfferingCostsIncludedInAccountsPayable	423458	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	45	usd
CY2022	bwv	Recognition Of Contingent Warrant Liability Upon Issuance Of Common Stock In Private Placement RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement	75431	usd
CY2022	bwv	Incremental Fair Value Of Preferred Investment Options Exchanged With Private Placement IncrementalFairValueOfPreferredInvestmentOptionsExchangedWithPrivatePlacement	860204	usd
CY2022	bwv	Payment Of Accrued Bonus Through Related Party Receivable PaymentOfAccruedBonusThroughRelatedPartyReceivable	140000	usd
CY2022	bwv	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	6	usd
CY2021Q4	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	4-for-1 (4:1) stock split
CY2022Q1	bwv	Initial Public Offering Shares InitialPublicOfferingShares	2222222	shares
CY2022Q1	bwv	Price Per Share PricePerShare	9
CY2022Q1	bwv	Initial Public Offering InitialPublicOffering	Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were $17.1 million.
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	5626365	shares
CY2022	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	33100000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	25800000	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	22300000	usd
CY2022Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	19400000	usd
CY2022	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of common stock (for transactions incurred prior to the consummation of the IPO), stock-based compensation, accrued research and development expenses and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	72172	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	49832	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2409128	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1055515	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of December 31, 2022 and 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021	bwv	Nonfinancial Assets Or Liabilities Recorded At Fair Value On A Nonrecurring Basis Description NonfinancialAssetsOrLiabilitiesRecordedAtFairValueOnANonrecurringBasisDescription	none of the Company’s non-financial assets or liabilities were recorded at fair value on a non-recurring basis.
CY2022	bwv	Nonfinancial Assets Or Liabilities Recorded At Fair Value On A Nonrecurring Basis Description NonfinancialAssetsOrLiabilitiesRecordedAtFairValueOnANonrecurringBasisDescription	none of the Company’s non-financial assets or liabilities were recorded at fair value on a non-recurring basis.
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	14021	usd
CY2022	bwv	Fair Value At Issuance1 FairValueAtIssuance1	75431	usd
CY2022	us-gaap	Asset At Fair Value Changes In Fair Value Resulting From Changes In Assumptions AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions	61410	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	14021	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	15000	usd
CY2022Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	800000	usd
CY2021Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	300000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	225000	usd
CY2022	bwv	Accrued Research And Development AccruedResearchAndDevelopment	847747	usd
CY2021	bwv	Accrued Research And Development AccruedResearchAndDevelopment	300182	usd
CY2022Q4	bwv	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	125000	usd
CY2021Q4	bwv	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	246236	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	1132859	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	234265	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	177600	usd
CY2022	bwv	Options To Purchase Shares Of Common Stock OptionsToPurchaseSharesOfCommonStock	1392654	shares
CY2021	bwv	Options To Purchase Shares Of Common Stock OptionsToPurchaseSharesOfCommonStock	780640	shares
CY2022	bwv	Private Placement Warrants PrivatePlacementWarrants	5264274	shares
CY2021	bwv	Series Seed Preferred Stock SeriesSeedPreferredStock	4584552	shares
CY2022	bwv	Total Number Of Shares TotalNumberOfShares	6656928	shares
CY2021	bwv	Total Number Of Shares TotalNumberOfShares	5365192	shares
CY2022Q4	bwv	Prepaids Research And Development PrepaidsResearchAndDevelopment	231981	usd
CY2021Q4	bwv	Prepaids Research And Development PrepaidsResearchAndDevelopment	203910	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	148789	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4842	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	88462	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	25799	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	469232	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	234551	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	38750	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1150000	shares
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15724957	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3200000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15265228	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3200000	shares
CY2022Q1	bwv	Aggregate Purchase Shares AggregatePurchaseShares	2222222	shares
CY2022Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	9
CY2022Q1	us-gaap	Underwriting Expense Ratio UnderwritingExpenseRatio	0.08	pure
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	17100000	usd
CY2022Q1	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	111111	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	10.35
CY2022Q4	us-gaap	Commitments Fair Value Disclosure CommitmentsFairValueDisclosure	10000	usd
CY2022Q4	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	200000	shares
CY2022Q4	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	254000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y6M
CY2022Q4	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.9636	pure
CY2022Q4	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0409	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	5000000	shares
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	1
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	2
CY2022	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	459729	shares
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.23
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	600000	usd
CY2022	bwv	Remaining Shares RemainingShares	4500000	shares
CY2022Q2	us-gaap	Other Expenses OtherExpenses	6900000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022Q2	us-gaap	Shares Issued SharesIssued	590406	shares
CY2022	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	6.65
CY2022Q2	bwv	Agent Fee Percentage AgentFeePercentage	0.075	pure
CY2022Q2	bwv	Management Fee Percentage ManagementFeePercentage	0.01	pure
CY2022Q2	bwv	Out Of Pocket Expenses OutOfPocketExpenses	85000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	70849	shares
CY2022Q2	bwv	Percentage Of Purchase Warrants PercentageOfPurchaseWarrants	0.06	pure
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.46875
CY2022Q2	bwv	Warrants Issuable Shares WarrantsIssuableShares	70849	shares
CY2022	bwv	Aggregate Percentage AggregatePercentage	0.02	pure
CY2022Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1180812	shares
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.546
CY2022	bwv	Agent Fee Percentage AgentFeePercentage	0.075	pure
CY2022	bwv	Management Fee Percentage ManagementFeePercentage	0.01	pure
CY2022	bwv	Out Of Pocket Expenses OutOfPocketExpenses	85000	usd
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	220997	shares
CY2022	bwv	Percentage Of Common Stock Shares PercentageOfCommonStockShares	0.06	pure
CY2022	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	298346	shares
CY2022	bwv	Warrants Issuable Shares WarrantsIssuableShares	70849	shares
CY2022	bwv	Percentage Subscription PercentageSubscription	0.02	pure
CY2022	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	70849	shares
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	8000	usd
CY2022	bwv	Contigent Warrant Liability Description ContigentWarrantLiabilityDescription	The remaining 227,497 August Contingent Warrants were measured as a liability upon the close of the August Private Placement.
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	39000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	298346	shares
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	14000	usd
CY2022	bwv	Conversion Price Per Shares ConversionPricePerShares	1.52
CY2022	bwv	Underwritten Public Offering Netting Proceeds UnderwrittenPublicOfferingNettingProceeds	50000000	usd
CY2022	bwv	Offering Price Percentage OfferingPricePercentage	3	pure
CY2022	bwv	Cumulative Dividends Per Share CumulativeDividendsPerShare	0.08	pure
CY2021Q4	us-gaap	Cumulative Dividends CumulativeDividends	1489803	usd
CY2021Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	1.3
CY2022Q4	us-gaap	Cumulative Dividends CumulativeDividends	1586162	usd
CY2022Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	1.38
CY2022Q1	us-gaap	Shares Issued SharesIssued	1600000	shares
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2600000	shares
CY2022	bwv	Issuance Options IssuanceOptions	1041894	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.4
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2.1	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0.1	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	72223	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	32517	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	700000	usd
CY2022	us-gaap	Insured Financial Obligations With Credit Deterioration Remaining Weighted Average Contract Period InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod	P1Y10M20D
CY2022	us-gaap	Lease Cost LeaseCost	5500	usd
CY2022	bwv	Rentals Deposit RentalsDeposit	15000	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	0	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	0	usd
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company entered into a month-to-month lease in Cincinnati, Ohio, with an unrelated party in April 2021 with monthly payments of approximately $500 per month.
CY2022	us-gaap	Related Party Costs RelatedPartyCosts	500	usd
CY2022Q2	us-gaap	Short Term Lease Payments ShortTermLeasePayments	14000	usd
CY2022	us-gaap	Loss Contingency Date Of Dismissal LossContingencyDateOfDismissal	2023-04-30
CY2022Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1000000	usd
CY2022Q4	us-gaap	Legal Fees LegalFees	50000	usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	93466	shares
CY2022Q4	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	111111	shares
CY2022Q4	us-gaap	Commitments Fair Value Disclosure CommitmentsFairValueDisclosure	264000	usd
CY2022Q4	us-gaap	Loss Contingency Range Of Possible Loss Portion Not Accrued LossContingencyRangeOfPossibleLossPortionNotAccrued	1300000	usd
CY2022	bwv	Royalty Payments Percentage RoyaltyPaymentsPercentage	0.20	pure
CY2022	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	63000	usd
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	435000	usd
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	22000	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	200000	usd
CY2022Q4	us-gaap	Due From Related Parties DueFromRelatedParties	36000	usd
CY2021Q4	us-gaap	Due From Related Parties DueFromRelatedParties	153000	usd
CY2021	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	140000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12500000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	12100000	usd
CY2022	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations	8500000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.80	pure
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2986738	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1120155	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	885176	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	308552	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	106171	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	186573	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	55500	usd
CY2022Q4	bwv	Deferred Tax Assets License Agreement DeferredTaxAssetsLicenseAgreement	82626	usd
CY2021Q4	bwv	Deferred Tax Assets License Agreement DeferredTaxAssetsLicenseAgreement	59685	usd
CY2022Q4	bwv	Deferred Tax Assets Other Accrued Expenses DeferredTaxAssetsOtherAccruedExpenses	65886	usd
CY2021Q4	bwv	Deferred Tax Assets Other Accrued Expenses DeferredTaxAssetsOtherAccruedExpenses	14636	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4515551	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1356147	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4512546	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1353673	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3005	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2474	usd
CY2022Q4	bwv	Deferred Tax Fixed Assets DeferredTaxFixedAssets	3005	usd
CY2021Q4	bwv	Deferred Tax Fixed Assets DeferredTaxFixedAssets	2474	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3005	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2474	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3200000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2818164000000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-717640000000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-501277000000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-91233000000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-16477000000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	194705000000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	9501000000	usd
CY2022	bwv	Effective Income Tax Rate Reconciliation Nondeductible Expense State Rate Adjustment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment	19600000000	usd
CY2021	bwv	Effective Income Tax Rate Reconciliation Nondeductible Expense State Rate Adjustment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStateRateAdjustment	119414000000	usd
CY2022	bwv	Others Accrued Liabilities Current OthersAccruedLiabilitiesCurrent	-37260000000	usd
CY2021	bwv	Others Accrued Liabilities Current OthersAccruedLiabilitiesCurrent	4228000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3158873000000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	675730000000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	11517	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5493	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17010	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	17010	usd
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	1	pure
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	bwv	Preferred Stock Value1 PreferredStockValue1		usd
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	15400000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Other Operating Income OtherOperatingIncome		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.26
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12271449	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3200000	shares
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2022	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges		usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts		usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2021	bwv	Recognition Of Contingent Warrant Liability Upon Issuance Of Common Stock In Private Placement RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement		usd
CY2021	bwv	Incremental Fair Value Of Preferred Investment Options Exchanged With Private Placement IncrementalFairValueOfPreferredInvestmentOptionsExchangedWithPrivatePlacement		usd
CY2021	bwv	Payment Of Accrued Bonus Through Related Party Receivable PaymentOfAccruedBonusThroughRelatedPartyReceivable		usd
CY2021	bwv	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants		usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2022	bwv	Series Seed Preferred Stock SeriesSeedPreferredStock		shares
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther		usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch		usd
CY2022	bwv	Income Tax Expense Provision For Income Taxes IncomeTaxExpenseProvisionForIncomeTaxes		usd
CY2021	bwv	Income Tax Expense Provision For Income Taxes IncomeTaxExpenseProvisionForIncomeTaxes		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions		usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001782107

Files In Submission

Name	View Source	Status
bwv-20221231_cal.xml	Edgar Link	unprocessable
0001213900-23-018635-index-headers.html	Edgar Link	pending
0001213900-23-018635-index.html	Edgar Link	pending
0001213900-23-018635.txt	Edgar Link	pending
0001213900-23-018635-xbrl.zip	Edgar Link	pending
bwv-20221231_lab.xml	Edgar Link	unprocessable
bwv-20221231.xsd	Edgar Link	pending
f10k2022ex23-1_bluewater.htm	Edgar Link	pending
f10k2022ex31-1_bluewater.htm	Edgar Link	pending
f10k2022ex31-2_bluewater.htm	Edgar Link	pending
f10k2022ex32-1_bluewater.htm	Edgar Link	pending
f10k2022ex32-2_bluewater.htm	Edgar Link	pending
f10k2022_bluewater.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
bwv-20221231_def.xml	Edgar Link	unprocessable
bwv-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_bluewater_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONCO
Onconetix, Inc. Stock $onco

2023 Q1 Form 10-K Financial Statement

#000121390023018635 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO Onconetix, Inc. Stock $onco

2023 Q1 Form 10-K Financial Statement

#000121390023018635 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO
Onconetix, Inc. Stock $onco